• Studies comparing clopidogrel to newer P2Y12 antagonists have demonstrated benefit in cardiovascular outcomes for the new agents, at a cost of slight but significant increased major bleeding
• Compared to standard dose, double dose clopidogrel for the first 6 days following ACS demonstrated no overall vascular benefit, and increased major bleeding. However, in those who underwent PCI, double dose clopidogrel demonstrated additional significant benefit in reducing major vascular events.